The FDA has approved Evrysdi (risdiplam) to treat patients two months and older with spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease. The FDA has approved Evrysdi (risdiplam) to treat patients two months and older with spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease.

Content Original Link:

http://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy